세계의 줄기세포 제조 시장 : 제품별, 용도별, 유통 채널별, 최종사용자별, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2025-2033년)

The stem cell manufacturing landscape is evolving rapidly, fueled by significant clinical trial successes and the approval of new therapies that are transforming the regenerative medicine field. These advancements have validated the therapeutic potential of stem cell technologies, driving increased interest and confidence among researchers, investors, and healthcare providers. As a result, the market has experienced substantial growth, with its valuation reaching approximately US$ 24.26 billion in 2024. This upward trajectory is expected to continue, with projections estimating the market will expand to a remarkable US$ 65.49 billion by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 11.96% during the forecast period from 2025 to 2033, underscoring the strong momentum and expanding opportunities within the industry.

A key factor contributing to this rapid expansion is the surge in strategic outsourcing and increased investments from major pharmaceutical companies. These collaborations and financial commitments are crucial in addressing longstanding manufacturing bottlenecks that have challenged the scalability and cost-effectiveness of stem cell therapies. By partnering with specialized contract manufacturing organizations (CMOs) and investing in cutting-edge production technologies, pharmaceutical players are enhancing manufacturing capacity and streamlining processes. This strategic outsourcing not only alleviates operational constraints but also accelerates the pace at which therapies can be commercialized and brought to market on a global scale.

Noteworthy Market Developments

Leading corporations in the stem cell manufacturing market are making substantial investments to position themselves for anticipated future demand, signaling a robust commitment to scaling production capabilities and advancing the field. Lonza, a key player in the industry, is investing approximately 500 million Swiss francs into its Vacaville facility, which already features an impressive bioreactor capacity of around 330,000 liters. This significant financial commitment reflects Lonza's strategic focus on expanding its manufacturing infrastructure to meet the growing needs of regenerative medicine and cell therapy developers.

Similarly, Thermo Fisher Scientific is making bold moves to enhance its research and manufacturing capabilities. The company is investing $1.4 billion in research and development, alongside expanding its manufacturing footprint by more than 45,000 square feet in New York alone. This expansion is part of a broader strategy to increase production efficiency, accelerate innovation, and support a growing pipeline of stem cell therapies. Thermo Fisher's commitment to both R&D and physical infrastructure highlights the critical importance of integrating scientific advancement with scalable manufacturing solutions.

Adding to this momentum, Lonza is also developing a new 300,000-square-foot facility in Houston, further emphasizing the industry's aggressive approach to scaling capacity. This expansion not only demonstrates Lonza's dedication to meeting future commercial demand but also reflects a broader trend within the stem cell manufacturing market toward building state-of-the-art facilities capable of supporting high-volume production.

Core Growth Drivers

The rising prevalence of chronic diseases is a significant factor driving the growth of the regenerative medicine market, including stem cell manufacturing. Chronic illnesses such as diabetes, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions have become increasingly common worldwide, placing a substantial burden on healthcare systems and patients alike. Traditional treatment options often focus on managing symptoms rather than offering curative solutions, leading to a growing demand for innovative therapies that can repair or replace damaged tissues and restore normal function. Regenerative medicine, with its potential to harness the body's own healing mechanisms, presents a promising avenue for addressing these unmet medical needs.

Emerging Opportunity Trends

The integration of artificial intelligence (AI) into predictive quality control (QC) represents a transformative opportunity for the stem cell manufacturing market, promising to significantly enhance efficiency and product reliability. Traditional QC methods in stem cell manufacturing often rely on manual inspections and periodic sampling, which can be time-consuming and prone to inconsistencies. In contrast, AI-driven systems leverage advanced algorithms capable of processing vast amounts of data in real time, allowing for continuous monitoring and early detection of potential issues during the manufacturing process. This capability not only improves the accuracy of quality assessments but also reduces the risk of batch failures, thereby increasing overall manufacturing yield and consistency.

Barriers to Optimization

High manufacturing costs and the inherent complexity of producing stem cell therapies pose significant challenges that could impede the widespread adoption of these treatments and potentially slow market growth. Stem cell manufacturing involves intricate processes that demand strict adherence to quality standards, sterile environments, and specialized equipment. These factors contribute to elevated production expenses, which in turn can make therapies prohibitively expensive for many healthcare providers and patients. The financial barrier created by these costs limits accessibility and adoption, especially in regions or healthcare systems with constrained budgets.

Detailed Market Segmentation

By Product Type, the consumables and kits segment holds a crucial position within the stem cell manufacturing market, commanding a substantial revenue share of 42.51%. This segment forms the backbone of the entire industry, as consumables and kits are indispensable at every stage of the stem cell lifecycle-from initial research and development to scale-up and commercial production. The recurring nature of demand for these products stems from their essential role in maintaining cell viability, supporting cell growth, and ensuring the precision required for consistent manufacturing outcomes. Without reliable and high-quality consumables, the entire process of stem cell manufacturing would face significant challenges, making this segment foundational to the industry's overall success.

By Distribution Channel, the direct sales channel dominates the stem cell manufacturing market, generating over 69.93% of the total market revenue. This overwhelming share is largely attributed to the highly sensitive and complex nature of stem cell products, which demand specialized handling and distribution processes. Unlike conventional pharmaceutical products, stem cell therapies are living biological materials that require precise conditions to maintain their viability and therapeutic efficacy. The intricate nature of these products necessitates direct interaction between manufacturers and end-users, such as hospitals, clinics, and research institutions, ensuring strict quality control and compliance with regulatory standards throughout the supply chain.

By End Users, Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are controlling the largest 44.67% market share. There are a few companies that hold the dominant position in the market, but they are collectively the commercial engine of the industry. These entities in the stem cell manufacturing market possess the financial resources, infrastructure, and regulatory expertise necessary to navigate the long and expensive path from research to commercialization.

By Application, the clinical applications segment holds a commanding position within the stem cell manufacturing market, accounting for 52.32% of the total market share. This significant share reflects the critical role clinical applications play in transforming the scientific potential of stem cell research into real-world medical treatments. As the field of regenerative medicine continues to advance, clinical applications serve as the primary avenue through which promising laboratory discoveries are translated into therapies that can improve patient outcomes. The emphasis on clinical use underscores the growing confidence in stem cell technologies as viable treatment options for a range of diseases and conditions.

Segment Breakdown

By Product

• Stem Cell Lines
• Mesenchymal Stem Cells
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Induced Pluripotent Stem Cells
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Hematopoietic Stem Cells
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Embryonic Stem Cells
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Neural Stem Cells
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Others
• Differentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Undifferentiated
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Consumables and Kits
• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• Consumables and Kits

By Type

• Culture Media
• Growth Factors & Cytokines
• Culture ware and Vessels
• T-Flasks
• Vials
• Cell Culture Dishes / Multi-Well Plates
• Cell Culture Bags
• Others
• Others

By Application

• Research Applications
• Disease Modelling
• Drug Discovery & Toxicology Testing
• Others
• Clinical Applications
• Autologous Therapies
• Allogeneic Therapies
• Cell & Tissue Banking
• Instruments
• Bioreactors & Cell Expansion Systems
• Cell Sorters & Separation Devices
• Flow Cytometers & Analysers
• Software and Services

By Application

• Research Applications
• Disease Modelling
• Drug Discovery & Toxicology Testing
• Others
• Clinical Applications
• Autologous Therapies
• Allogeneic Therapies
• Cell & Tissue Banking

By Distribution Channel

• Direct Sales
• Distributors

By End User

• CROs, Pharmaceutical and Biotechnology Companies
• Academic & Research Institutions
• Hospitals & Surgical Centres
• Cell & Tissue Banks
• Other Users (Regenerative Medicine Startups, Diagnostic Firms)

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia & New Zealand
• ASEAN
• Cambodia
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America stands out as the undisputed global leader in the stem cell manufacturing market, propelled by a strong blend of well-established regulatory frameworks, significant public funding, and a thriving biotechnology ecosystem. The region's dominance is anchored by its ability to create a conducive environment for research, development, and commercialization of stem cell technologies. Regulatory agencies in the United States and Canada have developed clear and structured pathways that facilitate the approval and oversight of stem cell products, giving companies the confidence to invest heavily in innovation and scale-up manufacturing capabilities. This regulatory clarity is a critical factor that distinguishes North America from other regions, reducing uncertainties and accelerating the time to market for new therapies.
• The market's anticipated share of over 49.58% by 2033 highlights North America's commanding presence in the industry. This leading position is reinforced by the substantial financial resources directed toward stem cell research and manufacturing infrastructure. Both federal and state governments in the U.S. have launched initiatives and funding programs that support biotechnology ventures, clinical trials, and manufacturing advancements. These investments not only stimulate industry growth but also foster collaboration between academia, private companies, and healthcare providers.

Leading Market Participants

• Thermo Fisher Scientific
• Lonza
• nacalai
• BioRad
• Merck
• FujiFilm
• CellGenix
• Teknova
• Sartorius
• Stemcell Technologies
• Miltenyi Biotec
• Eppendorf
• Beckman Coulter
• Takara Bio
• Bio-Techne
• PromoCell
• Wellsky
• BD
• Corning Life Sciences
• HiMedia
• REPROCELL
• Other Prominent Players

Table of Content

Chapter 1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

Chapter 2. Research Methodology

• 2.1. Qualitative Research
  • 2.1.1. Primary & Secondary Sources
• 2.2. Quantitative Research
  • 2.2.1. Primary & Secondary Sources
• 2.3. Breakdown of Primary Research Respondents, By Region
• 2.4. Assumption for the Study
• 2.5. Market Size Estimation
• 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Stem Cell Manufacturing Market

Chapter 4. Global Stem Cell Manufacturing Market Overview

• 4.1. Industry Value Chain Analysis
  • 4.1.1. Material Provider
  • 4.1.2. Manufacturer
  • 4.1.3. Distributor
  • 4.1.4. End User
• 4.2. Industry Outlook
  • 4.2.1. Global GDP and Healthcare Infrastructure
  • 4.2.2. Growth in Pharmaceutical, Biotechnology, and CRO/CDMO
  • 4.2.3. Growing Chronic Disease Burden
  • 4.2.4. Transition from Stem Cell Experimental Research to Approved Clinical Therapies
  • 4.2.5. Stem Cell Manufacturing Workflow and Emerging Technologies
    • 4.2.5.1. Embryonic Stem Cells (ESCs)
    • 4.2.5.2. Induced Pluripotent Stem Cells (iPSCs)
    • 4.2.5.3. Adult Stem Cells (ASCs)
  • 4.2.6. Commonly Used Stem Cell Types
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of Substitutes
  • 4.3.4. Threat of New Entrants
  • 4.3.5. Degree of Competition
• 4.4. Market Dynamics and Trends
  • 4.4.1. Growth Drivers
  • 4.4.2. Challenges
  • 4.4.3. Opportunity
  • 4.4.4. Key Trends
• 4.5. Market Growth and Outlook
  • 4.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
  • 4.5.2. Price Trend Analysis
• 4.6. Competition Dashboard
  • 4.6.1. Market Concentration Rate
  • 4.6.2. Company Market Share Analysis (Value %), 2024
  • 4.6.3. Competitor Mapping & Benchmarking

Chapter 5. Global Stem Cell Manufacturing Market Analysis, By Product Type

• 5.1. Key Insights
• 5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 5.2.1. Stem Cell Lines
    • 5.2.1.1. Mesenchymal Stem Cells
      • 5.2.1.1.1. Differentiated
        • 5.2.1.1.1.1. Instruments
• 5.2.1.1.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.1.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.1.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.1.1.2. Consumables and Kits
• 5.2.1.1.1.2.1. Culture Media
• 5.2.1.1.1.2.2. Growth Factors & Cytokines
• 5.2.1.1.1.2.3. Culture ware and Vessels
  • 5.2.1.1.2. Undifferentiated
    • 5.2.1.1.2.1. Instruments
• 5.2.1.1.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.1.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.1.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.1.2.2. Consumables and Kits
• 5.2.1.1.2.2.1. Culture Media
• 5.2.1.1.2.2.2. Growth Factors & Cytokines
• 5.2.1.1.2.2.3. Culture ware and Vessels
  • 5.2.1.2. Induced Pluripotent Stem Cells
    • 5.2.1.2.1. Differentiated
      • 5.2.1.2.1.1. Instruments
• 5.2.1.2.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.2.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.2.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.2.1.2. Consumables and Kits
• 5.2.1.2.1.2.1. Culture Media
• 5.2.1.2.1.2.2. Growth Factors & Cytokines
• 5.2.1.2.1.2.3. Culture ware and Vessels
  • 5.2.1.2.2. Undifferentiated
    • 5.2.1.2.2.1. Instruments
• 5.2.1.2.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.2.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.2.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.2.2.2. Consumables and Kits
• 5.2.1.2.2.2.1. Culture Media
• 5.2.1.2.2.2.2. Growth Factors & Cytokines
• 5.2.1.2.2.2.3. Culture ware and Vessels
  • 5.2.1.3. Hematopoietic Stem Cells
    • 5.2.1.3.1. Differentiated
      • 5.2.1.3.1.1. Instruments
• 5.2.1.3.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.3.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.3.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.3.1.2. Consumables and Kits
• 5.2.1.3.1.2.1. Culture Media
• 5.2.1.3.1.2.2. Growth Factors & Cytokines
• 5.2.1.3.1.2.3. Culture ware and Vessels
  • 5.2.1.3.2. Undifferentiated
    • 5.2.1.3.2.1. Instruments
• 5.2.1.3.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.3.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.3.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.3.2.2. Consumables and Kits
• 5.2.1.3.2.2.1. Culture Media
• 5.2.1.3.2.2.2. Growth Factors & Cytokines
• 5.2.1.3.2.2.3. Culture ware and Vessels
  • 5.2.1.4. Embryonic Stem Cells
    • 5.2.1.4.1. Differentiated
      • 5.2.1.4.1.1. Instruments
• 5.2.1.4.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.4.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.4.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.4.1.2. Consumables and Kits
• 5.2.1.4.1.2.1. Culture Media
• 5.2.1.4.1.2.2. Growth Factors & Cytokines
• 5.2.1.4.1.2.3. Culture ware and Vessels
  • 5.2.1.4.2. Undifferentiated
    • 5.2.1.4.2.1. Instruments
• 5.2.1.4.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.4.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.4.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.4.2.2. Consumables and Kits
• 5.2.1.4.2.2.1. Culture Media
• 5.2.1.4.2.2.2. Growth Factors & Cytokines
• 5.2.1.4.2.2.3. Culture ware and Vessels
  • 5.2.1.5. Neural Stem Cells
    • 5.2.1.5.1. Differentiated
      • 5.2.1.5.1.1. Instruments
• 5.2.1.5.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.5.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.5.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.5.1.2. Consumables and Kits
• 5.2.1.5.1.2.1. Culture Media
• 5.2.1.5.1.2.2. Growth Factors & Cytokines
• 5.2.1.5.1.2.3. Culture ware and Vessels
  • 5.2.1.5.2. Undifferentiated
    • 5.2.1.5.2.1. Instruments
• 5.2.1.5.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.5.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.5.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.5.2.2. Consumables and Kits
• 5.2.1.5.2.2.1. Culture Media
• 5.2.1.5.2.2.2. Growth Factors & Cytokines
• 5.2.1.5.2.2.3. Culture ware and Vessels
  • 5.2.1.6. Others
    • 5.2.1.6.1. Differentiated
      • 5.2.1.6.1.1. Instruments
• 5.2.1.6.1.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.6.1.1.2. Cell Sorters & Separation Devices
• 5.2.1.6.1.1.3. Flow Cytometers & Analysers
  • 5.2.1.6.1.2. Consumables and Kits
• 5.2.1.6.1.2.1. Culture Media
• 5.2.1.6.1.2.2. Growth Factors & Cytokines
• 5.2.1.6.1.2.3. Culture ware and Vessels
  • 5.2.1.6.2. Undifferentiated
    • 5.2.1.6.2.1. Instruments
• 5.2.1.6.2.1.1. Bioreactors & Cell Expansion Systems
• 5.2.1.6.2.1.2. Cell Sorters & Separation Devices
• 5.2.1.6.2.1.3. Flow Cytometers & Analysers
  • 5.2.1.6.2.2. Consumables and Kits
• 5.2.1.6.2.2.1. Culture Media
• 5.2.1.6.2.2.2. Growth Factors & Cytokines
• 5.2.1.6.2.2.3. Culture ware and Vessels
  • 5.2.2. Consumables and Kits
    • 5.2.2.1. By Type
      • 5.2.2.1.1. Culture Media
      • 5.2.2.1.2. Growth Factors & Cytokines
      • 5.2.2.1.3. Culture ware and Vessels
        • 5.2.2.1.3.1. T-Flasks
        • 5.2.2.1.3.2. Vials
        • 5.2.2.1.3.3. Cell Culture Dishes / Multi-Well Plates
        • 5.2.2.1.3.4. Cell Culture Bags
        • 5.2.2.1.3.5. Others
      • 5.2.2.1.4. Others
    • 5.2.2.2. By Application
      • 5.2.2.2.1. Research Applications
        • 5.2.2.2.1.1. Disease Modelling
        • 5.2.2.2.1.2. Drug Discovery & Toxicology Testing
        • 5.2.2.2.1.3. Others
      • 5.2.2.2.2. Clinical Applications
        • 5.2.2.2.2.1. Autologous Therapies
        • 5.2.2.2.2.2. Allogeneic Therapies
      • 5.2.2.2.3. Cell & Tissue Banking
  • 5.2.3. Instruments
    • 5.2.3.1. Bioreactors & Cell Expansion Systems
    • 5.2.3.2. Cell Sorters & Separation Devices
    • 5.2.3.3. Flow Cytometers & Analysers
  • 5.2.4. Software and Services

Chapter 6. Global Stem Cell Manufacturing Market Analysis, By Application

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 6.2.1. Research Applications
    • 6.2.1.1. Disease Modelling
    • 6.2.1.2. Drug Discovery & Toxicology Testing
    • 6.2.1.3. Others
  • 6.2.2. Clinical Applications
    • 6.2.2.1. Autologous Therapies
    • 6.2.2.2. Allogeneic Therapies
  • 6.2.3. Cell & Tissue Banking

Chapter 7. Global Stem Cell Manufacturing Market Analysis, By Distribution Channel

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 7.2.1. Direct Sales
  • 7.2.2. Distributors

Chapter 8. Global Stem Cell Manufacturing Market Analysis, By End Users

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 8.2.1. CROs, Pharmaceutical and Biotechnology Companies
  • 8.2.2. Academic & Research Institutions
  • 8.2.3. Hospitals & Surgical Centres
  • 8.2.4. Cell & Tissue Banks
  • 8.2.5. Other Users (Regenerative Medicine Startups, Diagnostic Firms)

Chapter 9. Global Stem Cell Manufacturing Market Analysis, By Region

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
  • 9.2.1. North America
    • 9.2.1.1. The U.S.
    • 9.2.1.2. Canada
    • 9.2.1.3. Mexico
  • 9.2.2. Europe
    • 9.2.2.1. Western Europe
      • 9.2.2.1.1. The UK
      • 9.2.2.1.2. Germany
      • 9.2.2.1.3. France
      • 9.2.2.1.4. Italy
      • 9.2.2.1.5. Spain
      • 9.2.2.1.6. Rest of Western Europe
    • 9.2.2.2. Eastern Europe
      • 9.2.2.2.1. Poland
      • 9.2.2.2.2. Russia
      • 9.2.2.2.3. Rest of Eastern Europe
  • 9.2.3. Asia Pacific
    • 9.2.3.1. China
    • 9.2.3.2. India
    • 9.2.3.3. Japan
    • 9.2.3.4. South Korea
    • 9.2.3.5. Australia & New Zealand
    • 9.2.3.6. ASEAN
      • 9.2.3.6.1. Cambodia
      • 9.2.3.6.2. Indonesia
      • 9.2.3.6.3. Malaysia
      • 9.2.3.6.4. Philippines
      • 9.2.3.6.5. Singapore
      • 9.2.3.6.6. Thailand
      • 9.2.3.6.7. Vietnam
    • 9.2.3.7. Rest of Asia Pacific
  • 9.2.4. Middle East & Africa
    • 9.2.4.1. UAE
    • 9.2.4.2. Saudi Arabia
    • 9.2.4.3. South Africa
    • 9.2.4.4. Rest of MEA
  • 9.2.5. South America
    • 9.2.5.1. Argentina
    • 9.2.5.2. Brazil
    • 9.2.5.3. Rest of South America

Chapter 10. North America Stem Cell Manufacturing Market Analysis

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By End Users
  • 10.2.5. By Country

Chapter 11. Europe Stem Cell Manufacturing Market Analysis

• 11.1. Key Insights
• 11.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 11.2.1. By Product Type
  • 11.2.2. By Application
  • 11.2.3. By Distribution Channel
  • 11.2.4. By End Users
  • 11.2.5. By Country

Chapter 12. Asia Pacific Stem Cell Manufacturing Market Analysis

• 12.1. Key Insights
• 12.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 12.2.1. By Product Type
  • 12.2.2. By Application
  • 12.2.3. By Distribution Channel
  • 12.2.4. By End Users
  • 12.2.5. By Country

Chapter 13. Middle East & Africa Stem Cell Manufacturing Market Analysis

• 13.1. Key Insights
• 13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 13.2.1. By Product Type
  • 13.2.2. By Application
  • 13.2.3. By Distribution Channel
  • 13.2.4. By End Users
  • 13.2.5. By Country

Chapter 14. South America Stem Cell Manufacturing Market Analysis

• 14.1. Key Insights
• 14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
  • 14.2.1. By Product Type
  • 14.2.2. By Application
  • 14.2.3. By Distribution Channel
  • 14.2.4. By End Users
  • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 15.1. Thermo Fisher Scientific
• 15.2. Lonza
• 15.3. nacalai
• 15.4. BioRad
• 15.5. Merck
• 15.6. FujiFilm
• 15.7. CellGenix
• 15.8. Teknova
• 15.9. Sartorius
• 15.10. Stemcell Technologies
• 15.11. Miltenyi Biotec
• 15.12. Eppendorf
• 15.13. Beckman Coulter
• 15.14. Takara Bio
• 15.15. Bio-Techne
• 15.16. PromoCell
• 15.17. Wellsky
• 15.18. BD
• 15.19. Corning Life Sciences
• 15.20. HiMedia
• 15.21. REPROCELL
• 15.22. Other Prominent Players

Chapter 16. Annexure

• 16.1. List of Secondary Sources
• 16.2. Key Country Markets - Macro Economic Outlook/Indicator